

## Highlights of This Issue 415

## SMALL MOLECULE THERAPEUTICS

- 417** The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors  
Matthew R. Farren, Rebecca C. Hennessey, Reena Shakya, Omar Elnaggar, Gregory Young, Kari Kendra, Yosef Landesman, Sivan Elloul, Marsha Crochiere, Boris Klebanov, Trinayan Kashyap, Christin E. Burd, and Gregory B. Lesinski  
*See related article, p. 428*
- 428** Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy  
Paul M. Tyler, Mariah M. Servos, Romy C. de Vries, Boris Klebanov, Trinayan Kashyap, Sharon Sacham, Yosef Landesman, Michael Dougan, and Stephanie K. Dougan  
*See related article, p. 417*
- 440** Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma  
Raghavendra Gowda, Gregory Kardos, Arati Sharma, Sanjay Singh, and Gavin P. Robertson
- 453** Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers  
Peng-Cheng Lv, Jyoti Roy, Karson S. Putt, and Philip S. Low
- 461** Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer  
N. Achini Bandara, Cody D. Bates, Yingjuan Lu, Emily K. Hoylman, and Philip S. Low
- 469** Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer  
Jie Li, Ruixin Wang, Yifan Kong, Meaghan M. Broman, Colin Carlock, Long Chen, Zhiguo Li, Elia Farah, Timothy L. Ratliff, and Xiaoqi Liu
- 480** Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A  
Yueh-Hsiung Kuo, En-Pei Isabel Chiang, Che-Yi Chao, Raymond L. Rodriguez, Pei-Yu Chou, Shu-Yao Tsai, Man-Hui Pai, and Feng-Yao Tang

## CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 494** Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth  
Marilena Tauro, Gemma Shay, Samer S. Sansil, Antonio Laghezza, Paolo Tortorella, Anthony M. Neuger, Hatem Soliman, and Conor C. Lynch
- 506** MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer  
Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, and Seiji Yano
- 516** Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma  
Hanyin Cheng, Vivian Chua, Connie Liao, Timothy J. Purwin, Mizue Terai, Ken Kageyama, Michael A. Davies, Takami Sato, and Andrew E. Aplin
- 529** Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications  
Nathaniel Edward Bennett Saidu, Gaëlle Noé, Olivier Cerles, Luc Cabel, Niloufar Kavian-Tessler, Sandrine Chouzenoux, Mathilde Bahuau, Christiane Chéreau, Carole Nicco, Karen Leroy, Bruno Borghese, François Goldwasser, Frédéric Batteux, and Jérôme Alexandre

## COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 540** The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics  
Sanne R. Martens-de Kemp, Arjen Brink, Ida H. van der Meulen, René X. de Menezes, Dennis E. te Beest, C. René Leemans, Victor W. van Beusechem, Boudewijn J.M. Braakhuis, and Ruud H. Brakenhoff


## CORRECTION

- 551** Correction: Enhanced GAB2 Expression Is Associated with Improved Survival in High-grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

# Table of Contents

## ABOUT THE COVER

Matrix metalloproteinase-2 (MMP-2) is highly expressed in the bone metastatic breast cancer environment. Treatment of mice with novel bone seeking MMP inhibitors (BMMPs) significantly reduced tumor burden and protected against cancer induced bone loss. Cover illustrates a representative trichrome stained tibial tissue section of bone metastatic breast cancer derived from mice treated with an MMP-2 selective BMMP. Bone (green) loss and MMP-2 activity are significantly mitigated in BMMP treated animals. For more details see article by Tauro and colleagues on page 494.



# Molecular Cancer Therapeutics

16 (3)

*Mol Cancer Ther* 2017;16:415-551.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/16/3>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).